source
- BioNTech, DualityBio weigh future of HER2 ADC after modest Phase 3 breast cancer resultsBioNTech and DualityBio are assessing next steps for their HER2-targeted antibody-drug conjugate trastuzumab pamirtecan after a Phase 3 trial in breast cancer. The trial met its primary endpoint,…
- TGA opens consultation on temporary rise in Australian medical device annual feesThe Therapeutic Goods Administration (TGA) in Australia announced a public consultation regarding a proposed temporary increase to the annual charges that medical device manufacturers must pay. Th…